Ocular Therapeutix, Inc. (OCUL) Stock Price

OCULStock

$10.88−12.36%52W

Market Cap$2.39B

P/E—

PEG Ratio—

Div yield—

Beta0.94

OCUL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)45.44%

Price vs S&P 500 (4W)24.52%

VGM Score46.41

Book Value / Share (Quarterly)$2.37

P/TBV (Annual)5.03x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)0.30%

Cash Flow / Share (Quarterly)$-1.16

Price vs S&P 500 (YTD)-23.16%

Gross Margin (TTM)87.11%

Net Profit Margin (TTM)-579.10%

EPS (TTM)$-1.41

10-Day Avg Trading Volume3.79M

EPS Excl Extra (TTM)$-1.41

Revenue Growth (5Y)24.45%

EPS (Annual)$-1.42

ROI (Annual)-36.65%

Gross Margin (Annual)87.35%

Net Profit Margin (5Y Avg)-221.35%

Cash / Share (Quarterly)$2.73

Revenue Growth QoQ (YoY)0.12%

ROA (Last FY)-32.91%

Revenue Growth TTM (YoY)-8.14%

EBITD / Share (TTM)$-1.44

ROE (5Y Avg)-79.74%

Operating Margin (TTM)-603.04%

Cash Flow / Share (Annual)$-1.00

P/B Ratio4.27x

P/B Ratio (Quarterly)4.13x

Net Income / Employee (Annual)$-818,300

EV / Revenue (TTM)32.51x

Net Interest Coverage (TTM)-5.44x

ROA (TTM)-45.97%

EPS Incl Extra (Annual)$-1.42

Current Ratio (Annual)15.39x

Quick Ratio (Quarterly)12.79x

3-Month Avg Trading Volume2.79M

52-Week Price Return-12.36%

Revenue / Employee (TTM)$160,200

Tangible BV / Share (Quarterly)$0.10

P/S Ratio (Annual)42.70x

Asset Turnover (Annual)0.06x

52-Week High$16.44

Operating Margin (5Y Avg)-256.39%

EPS Excl Extra (Annual)$-1.42

CapEx CAGR (5Y)70.24%

Tangible BV CAGR (5Y)6.23%

26-Week Price Return56.69%

Quick Ratio (Annual)15.11x

13-Week Price Return31.14%

Total Debt / Equity (Annual)0.11x

Current Ratio (Quarterly)13.11x

Enterprise Value$1.69B

Revenue / Share Growth (5Y)-0.63%

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)24.79%

Revenue / Employee (Annual)$159,800

Inventory Turnover (Annual)1.99x

Pretax Margin (Annual)-511.90%

Cash / Share (Annual)$3.41

3-Month Return Std Dev55.14%

Gross Margin (5Y Avg)90.11%

Net Income / Employee (TTM)$-927,500

ROE (Last FY)-40.64%

Net Interest Coverage (Annual)-189.25x

EPS Basic Excl Extra (Annual)$-1.42

Receivables Turnover (TTM)1.72x

Total Debt / Equity (Quarterly)0.14x

EPS Incl Extra (TTM)$-1.41

Receivables Turnover (Annual)1.65x

ROI (TTM)-52.40%

P/S Ratio (TTM)42.61x

Pretax Margin (5Y Avg)-221.35%

Revenue / Share (Annual)$0.28

Tangible BV / Share (Annual)$0.46

Price vs S&P 500 (52W)-30.67%

Year-to-Date Return-11.20%

5-Day Price Return-2.09%

EPS Normalized (Annual)$-1.42

ROA (5Y Avg)-31.60%

Net Profit Margin (Annual)-511.90%

Month-to-Date Return31.95%

Cash Flow / Share (TTM)$-0.83

EBITD / Share (Annual)$-1.42

Operating Margin (Annual)-519.75%

LT Debt / Equity (Annual)0.11x

ROI (5Y Avg)-43.97%

LT Debt / Equity (Quarterly)0.14x

EPS Basic Excl Extra (TTM)$-1.41

P/TBV (Quarterly)22.65x

P/B Ratio (Annual)3.95x

Inventory Turnover (TTM)1.95x

Pretax Margin (TTM)-579.10%

Book Value / Share (Annual)$3.03

Price vs S&P 500 (13W)28.35%

Beta0.94x

Revenue / Share (TTM)$0.23

ROE (TTM)-59.87%

52-Week Low$6.23

vGradeD

gGradeC

mGradeB

vgmGradeC

OCUL Earnings Surprise History

Q2 25-0.39est. -0.35

Q3 25-0.38est. -0.35

Q4 25-0.29est. -0.34

Q1 26-0.40est. -0.32

Q2 26-0.35est. -0.39

OCUL Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.28

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
OCULOcular Therapeutix, Inc.	D	C	B	$10.88
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Ocular Therapeutix, Inc.

Ocular Therapeutix is a biotechnology company developing innovative eye disease treatments using its proprietary hydrogel platform technology, which enables improved therapeutic delivery compared to traditional eye drops. The company's pipeline includes multiple product candidates across various ophthalmic indications, including the FDA-approved Dextenza. Its platform technology addresses key limitations of conventional eye-drop therapies, positioning the company to capture market share in large ophthalmic disease markets.